Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility

Antiviral Research

Volumn 153, Issue , 2018, Pages 95-100

  McKimm Breschkin, Jennifer L ^a   Barrett, Susan ^a   Wong, Frank Y K ^a   Pudjiatmoko, ^b   Azhar, Muhammad ^b   Selleck, Paul ^a   Davies, Kelly R ^a   Hartaningsih, Nining ^c   McGrane, James ^c  

^a CSIRO   (Australia)

^b INDONESIAN AGENCY FOR AGRICULTURAL RESEARCH AND DEVELOPMENT   (Indonesia)

^c FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS   (Indonesia)

Author keywords

Avian influenza; H5N1; Neuraminidase inhibitor; Oseltamivir; Resistance; Surveillance

Indexed keywords

OSELTAMIVIR; PERAMIVIR; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT; NA PROTEIN, INFLUENZA A VIRUS; VIRAL PROTEIN;

ACEH; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; AVIAN INFLUENZA (H5N1); BINDING KINETICS; CLADISTICS; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG BINDING; ENZYME ACTIVITY; HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS; IC50; IN VITRO STUDY; INDONESIA; INFLUENZA A VIRUS (H5N1); NONHUMAN; PRIORITY JOURNAL; VIRUS IDENTIFICATION; VIRUS ISOLATION; ANIMAL; ANTIVIRAL RESISTANCE; AVIAN INFLUENZA; CHICKEN; DRUG EFFECT; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MISSENSE MUTATION; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CHICKENS; DRUG RESISTANCE, VIRAL; GENOTYPE; INDONESIA; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; VIRAL PROTEINS;

EID: 85044614802     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2018.03.007     Document Type: Article

References (41)

1. Barrett, S., McKimm-Breschkin, J.L., Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal. Antivir. Res. 108 (2014), 30–35.
2. Barrett, S., Mohr, P.G., Schmidt, P.M., McKimm-Breschkin, J.L., Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. PLoS One, 6, 2011, e23627.
3. Boltz, D.A., Douangngeun, B., Phommachanh, P., Sinthasak, S., Mondry, R., Obert, C., Seiler, P., Keating, R., Suzuki, Y., Hiramatsu, H., Govorkova, E.A., Webster, R.G., Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J. Gen. Virol. 91 (2010), 949–959.
4. Chen, Y., Liang, W., Yang, S., Wu, N., Gao, H., Sheng, J., Yao, H., Wo, J., Fang, Q., Cui, D., Li, Y., Yao, X., Zhang, Y., Wu, H., Zheng, S., Diao, H., Xia, S., Chan, K.H., Tsoi, H.W., Teng, J.L., Song, W., Wang, P., Lau, S.Y., Zheng, M., Chan, J.F., To, K.K., Chen, H., Li, L., Yuen, K.Y., Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet, 2013, 10.1016/s0140-6736(13) 60903–60904.
5. Earhart, K.C., Elsayed, N.M., Saad, M.D., Gubareva, L.V., Nayel, A., Deyde, V.M., Abdelsattar, A., Abdelghani, A.S., Boynton, B.R., Mansour, M.M., Essmat, H.M., Klimov, A., Shuck-Lee, D., Monteville, M.R., Tjaden, J.A., Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J. Infect. Public Health 2 (2009), 74–80.
6. FAO, H7N9 Situation Update. 2017 http://www.fao.org/ag/againfo/programmes/en/empres/H7N9/situation_update.html. (Accessed 12 December 2017)
7. Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H., Xu, K., Xu, X., Lu, H., Zhu, W., Gao, Z., Xiang, N., Shen, Y., He, Z., Gu, Y., Zhang, Z., Yang, Y., Zhao, X., Zhou, L., Li, X., Zou, S., Zhang, Y., Li, X., Yang, L., Guo, J., Dong, J., Li, Q., Dong, L., Zhu, Y., Bai, T., Wang, S., Hao, P., Yang, W., Zhang, Y., Han, J., Yu, H., Li, D., Gao, G.F., Wu, G., Wang, Y., Yuan, Z., Shu, Y., Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368 (2013), 1888–1897.
8. Govorkova, E.A., Ilyushina, N.A., Marathe, B.M., McClaren, J.L., Webster, R.G., Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model. J. Virol. 84 (2010), 8042–8050.
9. Hall, T.A., BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41 (1999), 95–98.
10. Hartaningsih, N., Wibawa, H., Pudjiatmoko, Rasa, F.S., Irianingsih, S.H., Dharmawan, R., Azhar, M., Siregar, E.S., McGrane, J., Wong, F., Selleck, P., Allen, J., Broz, I., Torchetti, M.K., Dauphin, G., Claes, F., Sastraningrat, W., Durr, P.A., Surveillance at the molecular level: developing an integrated network for detecting variation in avian influenza viruses in Indonesia. Prev. Vet. Med. 120 (2015), 96–105.
11. Hurt, A.C., Besselaar, T.G., Daniels, R.S., Ermetal, B., Fry, A., Gubareva, L., Huang, W., Lackenby, A., Lee, R.T., Lo, J., Maurer-Stroh, S., Nguyen, H.T., Pereyaslov, D., Rebelo-de-Andrade, H., Siqueira, M.M., Takashita, E., Tashiro, M., Tilmanis, D., Wang, D., Zhang, W., Meijer, A., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015. Antivir. Res. 132 (2016), 178–185.
12. Hurt, A.C., Ernest, J., Deng, Y.M., Iannello, P., Besselaar, T.G., Birch, C., Buchy, P., Chittaganpitch, M., Chiu, S.C., Dwyer, D., Guigon, A., Harrower, B., Kei, I.P., Kok, T., Lin, C., McPhie, K., Mohd, A., Olveda, R., Panayotou, T., Rawlinson, W., Scott, L., Smith, D., D'Souza, H., Komadina, N., Shaw, R., Kelso, A., Barr, I.G., Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in oceania, South East Asia and South Africa. Antivir. Res. 83 (2009), 90–93.
13. Hurt, A.C., Holien, J.K., Parker, M., Kelso, A., Barr, I.G., Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83 (2009), 10366–10373.
14. Hurt, A.C., Lowther, S., Middleton, D., Barr, I.G., Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antivir. Res. 87 (2010), 361–366.
15. Ilyushina, N.A., Seiler, J.P., Rehg, J.E., Webster, R.G., Govorkova, E.A., Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog., 6, 2010 e1000933.
16. Kayali, G., El-Shesheny, R., Kutkat, M.A., Kandeil, A.M., Mostafa, A., Ducatez, M.F., McKenzie, P.P., Govorkova, E.A., Nasraa, M.H., Webster, R.G., Webby, R.J., Ali, M.A., Continuing threat of influenza (H5N1) virus circulation in Egypt. Emerg. Infect. Dis. 17 (2011), 2306–2308.
17. Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F.G., Sugaya, N., Kawaoka, Y., Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004), 759–765.
18. Kiso, M., Ozawa, M., Le, M.T., Imai, H., Takahashi, K., Kakugawa, S., Noda, T., Horimoto, T., Kawaoka, Y., Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J. Virol. 85 (2011), 4667–4672.
19. Landon, M.R., Amaro, R.E., Baron, R., Ngan, C.H., Ozonoff, D., McCammon, J.A., Vajda, S., Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. Chem. Biol. Drug Des. 71 (2008), 106–116.
20. Le, Q.M., Kiso, M., Someya, K., Sakai, Y.T., Nguyen, T.H., Nguyen, K.H., Pham, N.D., Ngyen, H.H., Yamada, S., Muramoto, Y., Horimoto, T., Takada, A., Goto, H., Suzuki, T., Suzuki, Y., Kawaoka, Y., Avian flu: isolation of drug-resistant H5N1 virus. Nature, 437, 2005, 1108.
21. Little, K., Leang, S.K., Butler, J., Baas, C., Harrower, B., Mosse, J., Barr, I.G., Hurt, A.C., Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill., 20, 2015.
22. McKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., Zambon, M., Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47 (2003), 2264–2272.
23. McKimm-Breschkin, J.L., Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respi Viruses 7:Suppl. 1 (2013), 25–36.
24. McKimm-Breschkin, J.L., Barrett, S., Pudjiatmoko, Azhar, M., Wong, F.Y., Selleck, P., Mohr, P.G., McGrane, J., Kim, M., I222 neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian clade 2.1 highly pathogenic avian influenza A(H5N1) viruses. PLoS One, 8, 2013, e66105.
25. McKimm-Breschkin, J.L., Rootes, C., Mohr, P.G., Barrett, S., Streltsov, V.A., In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir. J. Antimicrob. Chemother. 67 (2012), 1874–1883.
26. McKimm-Breschkin, J.L., Selleck, P.W., Usman, T.B., Johnson, M.A., Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 13 (2007), 1354–1357.
27. McKimm-Breschkin, J.L., Williams, J., Barrett, S., Jachno, K., McDonald, M., Mohr, P.G., Saito, T., Tashiro, M., Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J. Antimicrob. Chemother. 68 (2013), 2210–2221.
28. Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van-der-Werf, S., Schweiger, B., Opp, M., Paget, J., van-de-Kassteele, J., Hay, A., Zambon, M., Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15 (2009), 552–560.
29. Monto, A.S., McKimm-Breschkin, J.L., Macken, C., Hampson, A.W., Hay, A., Klimov, A., Tashiro, M., Webster, R.G., Aymard, M., Hayden, F.G., Zambon, M., Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 (2006), 2395–2402.
30. Nguyen, H.T., Nguyen, T., Mishin, V.P., Sleeman, K., Balish, A., Jones, J., Creanga, A., Marjuki, H., Uyeki, T.M., Nguyen, D.H., Nguyen, D.T., Do, H.T., Klimov, A.I., Davis, C.T., Gubareva, L.V., Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009–2011. Emerg. Infect. Dis. 19 (2013), 1963–1971.
31. Oakley, A.J., Barrett, S., Peat, T.S., Newman, J., Streltsov, V.A., Waddington, L., Saito, T., Tashiro, M., McKimm-Breschkin, J.L., Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J. Med. Chem. 53 (2010), 6421–6431.
32. OIE, Update on Avian Influenza in Animals (Types H5 and H7). 2017 http://www.oie.int/en/animal-health-in-the-world/update-on-avian-influenza/2017/. (Accessed 22 May 2017)
33. Okomo-Adhiambo, M., Nguyen, H.T., Sleeman, K., Sheu, T.G., Deyde, V.M., Garten, R.J., Xu, X., Shaw, M.W., Klimov, A.I., Gubareva, L.V., Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antivir. Res. 85 (2010), 381–388.
34. Potier, M., Mameli, L., Belisle, M., Dallaire, L., Melancon, S.B., Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl- alpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94 (1979), 287–296.
35. Takashita, E., Meijer, A., Lackenby, A., Gubareva, L., Rebelo-de-Andrade, H., Besselaar, T., Fry, A., Gregory, V., Leang, S.K., Huang, W., Lo, J., Pereyaslov, D., Siqueira, M.M., Wang, D., Mak, G.C., Zhang, W., Daniels, R.S., Hurt, A.C., Tashiro, M., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antivir. Res. 117 (2015), 27–38.
36. WHO, Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly. Epidemiol. Rec. 87 (2012), 369–374.
37. WHO, Human Infections with Avian Influenza A(H7N9) Virus -Summary of Surveillance and Investigation Findings. 2014 http://www.who.int/influenza/human_animal_interface/influenza_h7n9/riskassessment_h7n9_27june14.pdf. (Accessed 30 September 2014)
38. WHO, Cumulative Number of Confirmed Human Cases for Avian Influenza A(H5N1) Reported to WHO, 2003-2015. 2015 http://www.who.int/influenza/human_animal_interface/EN_GIP_20150717cumulativeNumberH5N1cases.pdf?ua=1. (Accessed 29 September 2015)
39. WHO, Cumulative Number of Confirmed Human Cases for Avian Influenza A(H5N1) Reported to WHO, 2003-2017. 2017 http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/. (Accessed 12 December 2017)
40. Yen, H.L., Ilyushina, N.A., Salomon, R., Hoffmann, E., Webster, R.G., Govorkova, E.A., Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81 (2007), 12418–12426.
41. Yen, H.L., McKimm-Breschkin, J.L., Choy, K.T., Wong, D.D., Cheung, P.P., Zhou, J., Ng, I.H., Zhu, H., Webby, R.J., Guan, Y., Webster, R.G., Peiris, J.S., Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio, 4, 2013.